Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952389 · ClinicalTrials.gov registry record · NA
Acupuncture Therapy for COVID-Related Olfactory Loss
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04952389: Completed NA study, sponsored by Mayo Clinic.
NCT04952389 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04952389, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19.
Primary Outcome
The 40-item UPSIT is a measurement of the ability to detect odors where microencapsulated odorants on a strip are released by scratching. Each item is scored from 0 (did not correctly detect the odor) to 1 (correctly detected the odor). Total scores range from 0-40 with higher scores indicating better smell and lower scores indicating worse smell.
Interventions
- DRUG Budesonide
- DEVICE Acupuncture Therapy
- OTHER Olfactory Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2023-06-09 |
| Phase | NA |
What the finished NCT04952389 record still lists
NCT04952389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Budesonide is the first listed.
NCT04952389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04952389 about?
NCT04952389 is a clinical study titled "Acupuncture Therapy for COVID-Related Olfactory Loss". This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19.
What is the current status of trial NCT04952389?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-12-07. Estimated completion is 2023-06-09.
What interventions are being tested in trial NCT04952389?
The interventions under investigation include: Budesonide (DRUG), Acupuncture Therapy (DEVICE), Olfactory Training (OTHER).
Who is sponsoring clinical trial NCT04952389?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04952389's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI